A. Pisula

Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study

K. Simon, A. Horban, E. Janczewska, 2016, Clinical and experimental hepatology.

Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study

K. Simon, A. Horban, E. Janczewska, 2016, Alimentary pharmacology & therapeutics.

Significant Decrease in the Prevalence of Anxiety and Depression after Hepatitis C Eradication

E. Janczewska, J. Jaroszewicz, J. Musialik, 2022, Journal of clinical medicine.

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis

A. Horban, E. Janczewska, R. Flisiak, 2015, Medicine.

Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters.

A. Szymczak, A. Urbańska, E. Janczewska, 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Prevalence of HCV genotypes in Poland – the EpiTer study

K. Simon, A. Horban, E. Janczewska, 2016, Clinical and experimental hepatology.

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study

K. Simon, A. Horban, E. Janczewska, 2019, Clinical and experimental hepatology.

Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters.

A. Szymczak, A. Urbańska, E. Janczewska, 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.